Skip to content

Evaluating the feasibility of a tailored physical therapy program for patients with metastatic breast cancer

Evaluating the feasibility of a tailored physical therapy program for patients with metastatic breast cancer - Tailored physical therapy for patients with metastatic breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45659
Enrollment
40
Registered
2017-02-27
Start date
2017-05-04
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Interventions

After a comprehensive intake, a tailored physical therapy program will be provided that consists of elements specifically designed for this population that best target the patients goal(s) related t

Sponsors

Nederlands Kanker Instituut
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) metastatic breast cancer; 2) At least 18 years of age; 3) hose WHO performance score of 0-2; 3) Able to read and write Dutch; and 4) having functional problems with activities of daily living.

Exclusion criteria

Exclusion criteria: 1) significant cognitive impairment; 2) symptomatic heart disease; 3) live outside of the greater Amsterdam area; 4) have complex and/or multi-morbid conditions requiring multidisciplinary rehabilitation.

Design outcomes

Primary

MeasureTime frame
Feasibility of the tailored physical therapy program in terms of uptake, safety, and goal attainment. Intervention adherence , and satisfaction of patients and physical therapists will be assessed for possible improvement of the intervention.

Secondary

MeasureTime frame
Activities of daily living (User-P questionnaire), and health related quality of life (EORTC QLQ-C30 questionnaire). Medical data concerning diagnosis, metastases, treatments and comorbidities will be obtained from the medical record only after explicit consent of patients.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)